Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Recruiting 23Completed 14Active not recruiting 14Not yet recruiting 10Unknown 7Terminated 4Withdrawn 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 3Leukemia 2Burkitt Lymphoma 2Recurrence 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1Bites and Stings 1

Interventions

Cyclophosphamide 48Methotrexate 33Cytarabine 27fludarabine 23fludarabine phosphate 22Rituximab 22Filgrastim 21Vincristine 19Busulfan 19Whole-Body Irradiation 18Mycophenolic Acid 18Dexamethasone 18Antilymphocyte Serum 17Cyclosporine 16Etoposide 15Tacrolimus 14Melphalan 14Calcium Dobesilate 14pegaspargase 12Peripheral Blood Stem Cell Transplantation 12Doxorubicin 12Radiotherapy 11Clofarabine 11Granulocyte Colony-Stimulating Factor 10Thiotepa 9Bortezomib 9thymoglobulin 8Dasatinib 8Asparaginase 8plerixafor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Precursor Cell Lymphoblastic Leukemia-Lymphoma × blinatumomab × Clear all
NCT04506086 2025-05-18

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 4 Terminated
10 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04785547 2024-01-16

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

St. Anna Kinderkrebsforschung

Phase 2 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04044560 2022-02-21

OZM-097

University of British Columbia

Phase 2 Terminated
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡